DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/200bac/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Sweden" report to their offering.
The Swedish pharmacy monopoly has been deregulated, leading to greater competition and a downward pressure on the price of pharmaceuticals. The number of pharmacies is likely to continue to rise rapidly in 2011, and slow down and stabilise from 2012 onwards.
In 2010, the largest pharmaceutical companies by sales were AstraZeneca, Pfizer, Roche, Wyeth and Novo Nordisk. The economic recession had a major impact on pharmaceutical companies, particularly the multinationals which have announced job cuts worldwide.
There are a number of small biologic companies in Sweden, as well as several multinationals which engage in biopharmaceutical R&D and production. In 2011, a total of 63 biotechnology R&D projects are under development at 35 companies. This excludes projects at AstraZeneca, which has around 40% of its global R&D workforce based in Sweden. The strength of R&D in Sweden bodes well for the future of the biotechnology industry. In terms of competition, in April 2011 Medivir announced it was to acquire BioPhausia, expanding its commercial activities in the Nordic countries.
Enhanced Strategic Intelligence
This highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. The report provides in-depth information, setting the pharmaceutical market in context:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
Healthcare Statistics
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Key Topics Covered:
- Macroenvironment
- Epidemiology
- Healthcare
- Regulatory Affairs
- Pricing & Reimbursement
- Distribution Channels
- Market Analysis
- Competition
- Otc Pharmaceuticals
- Generic Pharmaceuticals
- Biologics & Biosimilars
- Opportunities & Challenges
For more information visit http://www.researchandmarkets.com/research/200bac/the_pharmaceutical
Source: Espicom Business Intelligence Ltd